Yale Research to be Presented at 2021 ASCO Annual Meeting

Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) scientists and clinicians are presenting research studies at the 2021 Annual Virtual Meeting of the American Society of Clinical Oncology (ASCO) June 4-8. This year’s scientific program will feature more than 200 oral presentations and 1,900 poster presentations in over 20 disease-based and specialty tracks.

“The ASCO annual meeting provides the oncology community with an opportunity to showcase the latest advances in cancer research and care from throughout the world. Yale Cancer Center looks forward to sharing innovations in translational research from our laboratories and clinical trial outcomes during this year’s meeting,” said Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), Chief of Medical Oncology, Associate Cancer Center Director for Translational Research.

At this year’s meeting, the latest cancer research findings from YCC and SCH lead research teams will show new treatments and diagnostic advances in head and neck, gynecological, lung, prostate, and gastric cancers, melanoma, and many other areas of oncology. Some of the research highlights include:

Checkpoint Inhibitor–Based Therapies: New Immuno-Oncology Targets and Resistance Mechanisms

Educational Session Chair: Kurt A. Schalper, MD, PhD

Novel Opportunities for Interdisciplinary Care and Teleconsults in the Era of Digital Health

Panel Discussion Speaker: Nadine Housri, MD

Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).

Barbara Burtness, MD

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Yale Cancer Center looks forward to sharing innovations in translational research from our laboratories and clinical trial outcomes during this year’s meeting.

Dr. Roy S. Herbst

Alessandro Santin, MD

A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results

Patricia LoRusso, DO

Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.

Amer Zeidan, MBBS

First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).

Daniel P. Petrylak, MD

Treatment Efficacy Score (TES), a continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between trial arms in the I-SPY 2 trial.

Lajos Pusztai, MD, DPhil